Key result
Combined α/β-blockade provides a physiologically attractive and effective treatment alternative for hypertension resistant to ACE inhibitor/diuretic combinations.
Why the study?
Does combined α/β-blockade improve blood pressure control in patients with resistant or sympathetically mediated hypertension?
Does combined α/β-blockade improve blood pressure control in patients with resistant or sympathetically mediated hypertension?
Answers are grounded in this paper and cite their sources.
Combined α/β-blockade is an underutilized, physiologically attractive treatment alternative for resistant hypertension, particularly in patients with sympathetically mediated blood pressure elevations.
Angiotensin-converting enzyme inhibitor (ACEI)/diuretic and angiotensin receptor blocker (ARB)/diuretic combinations are currently the most commonly used drug combinations in the therapy for essential hypertension; these are highly effective. However, many patients are nonresponders in whom either additional drugs or different drugs are needed. The combination of an α-blocker with a β-blocker (α/β-blockade) is an attractive one, particularly for hypertension that may be resistant to an ACEI/diuretic combination. The magnitude of the antihypertensive effect is comparable to that of ACEI/diuretic combinations.1-4α/β-Blocker combinations lack the adverse metabolic effects and the increase in peripheral resistance associated with β-blocker monotherapy. Although β-blockers resemble ACEIs and ARBs in that they antagonize the renin-angiotensin system (RAS), combined α/β-blockade lowers blood pressure (BP) by mechanisms that differ from those of diuretics, ACEIs, and ARBs. Thus, the combination provides a mechanistic alternative in patients whose hypertension may be resistant to ACEI/diuretic and ARB/diuretic combinations. Despite these advantages, this drug combination appears to be underused. The purpose of this commentary is to (1) examine why; (2) explore the forms of hypertension for which its use might be most appropriate; (3) evaluate the drugs currently available; and (4) identify areas that warrant more research. Studies have documented that, on average, sympathetic tone is increased in patients with essential hypertension. Despite this, treatment aimed at volume and the RAS normalizes BP in most patients, indicating that in most cases antihypertensive treatment directed specifically at the sympathetic nervous system (SNS) is not needed. However, at least 3 factors argue for greater consideration of drug therapy directed at the SNS when other therapies have failed to control the BP: (1) the failure of ACEI/diuretic combinations to control BP in some cases, (2) the well-recognized increased SNS tone, and (3) clinical features that suggest that in many cases the SNS is playing a contributory role in driving hypertension (see below). A widespread misconception exists that β-blocker monotherapy is effective in treating sympathetically mediated (ie, “neurogenic”) elevation of BP. In fact, these agents do not reduce BP reactivity.5 In response to pressor stimuli, β-blockers block the increase in cardiac output and heart rate, but the pressor response is maintained by an increase in peripheral resistance.6 This is true even with adrenergic stimuli such as anxiety and epinephrine infusion.7, 8 Similarly, α-blocker monotherapy fails to reduce BP reactivity; the increase in peripheral resistance is blocked, but BP elevation is maintained by an increase in cardiac output.6 Monotherapy with other antihypertensive agents also fails to reduce the pressor response to sympathetic stimulation.9, 10 α/β-Blockade would seem better able to reduce BP reactivity because it blocks sympathetically mediated increases in both cardiac output and peripheral resistance. Only a few studies have been conducted to prove this.11-13 More than a dozen competing ACEIs and ARBs are currently under patent. Because of their effectiveness, extensive funding for research, and aggressive promotion, they are widely used. In contrast, fewer new antihypertensive agents directed at sympathetically mediated hypertension are available and less clinical and research attention has been given to this area. In addition, β-blockers and α-blockers have recently received considerable negative attention. Reviews conclude that ACEIs and ARBs are superior to β-blockers in primary prevention of stroke.14 Unlike β-blockers, these agents do not adversely affect glucose metabolism or cause fatigue. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) reported that the α-blocker doxazosin was inferior to the diuretic chlorthalidone in lowering BP and preventing cardiovascular events. This finding dissuaded many physicians from prescribing α-blockers and lessened appreciation for their well-documented value as add-on therapy in treating resistant hypertension. While the use of α-blocker monotherapy and β-blocker monotherapy has been appropriately discouraged, the benefits of combining α-blockers and β-blockers have received less attention. Earlier studies did not find the antihypertensive effect of combined //β-blockade with labetalol to be significantly greater than that of β-blocker monotherapy.15 However, labetalol is lipophilic and subject to considerable first-pass hepatic metabolism, with low bioavailability in the range of 25% to 33%, and with considerable interindividual variation in bioavailability.16, 17 As a result, many people taking labetalol do not achieve effective blood levels. In contrast, more recent studies that used an α1-blocker such as doxazosin or terazosin together with a nonlipophilic β-blocker have reported a greater antihypertensive effect, which is comparable to that of ACEI/diuretic combinations.1-4 There are subgroups of hypertensive patients in whom the use of α/β-blockade seems logical (ie, individuals whose BP elevation would appear to be maintained, to a large extent, by increased activation of the SNS). For example, individuals whose hypertension is resistant to treatment with an ACEI/diuretic combination might be expected to respond better to treatment directed at a different mechanism. People with labile hypertension might also seem better suited for treatment with α/β-blockade, given the prominent role of the SNS in BP fluctuation. α/β-Blockade could be expected to be more effective than ACEI /diuretic combinations in clinical circumstances in which reduction of sympathetically mediated BP elevation or fluctuation is needed, as in patients with labile hypertension, acute stroke, or dissecting aortic aneurysm. In treating poststroke BP elevation, treatment with α/β-blockade would seem more physiologically appropriate than treatment with diuretics that reduce volume and may increase viscosity and coagulability. Sympathetically mediated BP elevation is often encountered before surgical and other procedures and presents a clinical dilemma because it often results in the cancellation of scheduled procedures. Temporary pretreatment with α/β-blockade might be suitable. Finally, studies suggest that psychologic factors, such as the tendency to repress emotions or a history of childhood trauma, are associated with nonresponse to diuretics and ACEIs, while response to α/β-blockade is unaffected.18 As discussed above, earlier studies of α/β-blockade that employed labetalol probably understated the antihypertensive efficacy of the combination because of the low bioavailability of labetalol. Intravenous labetalol, unlike the oral version, is not subject to first-pass hepatic metabolism and is highly effective in treating hypertensive crises. However, when converting to oral α/β-blockade, bioavailability becomes an issue. Other lipophilic β-blockers, including carvedilol and metoprolol, also have bioavailability problems. The bioavailability of carvedilol, which combines both β-blocking and α-blocking effects, is only 16%,19 and the bioavailability of the long-acting carvedilol CR formulation is even lower. This would suggest that in some individuals, carvedilol may provide ineffective blood levels, even at the maximum recommended dosage. Nonlipophilic β-blockers such as atenolol, nadolol, and betaxolol are not subject to extensive first-pass metabolism and more consistently provide adequate blood levels.20 When given in combination with an α1-receptor blocker, such as doxazosin or terazosin, α/β-blockade can be expected to be more reliably achieved. This expectation is confirmed by the greater antihypertensive efficacy of these combinations. Importantly, when an α-blocker is used in combination with a β-blocker or an ACEI, its maximal effect is usually achieved at a relatively low dose (eg, 1 or 2 mg of doxazosin), obviating the need for multiple titration steps.4, 21, 22 Combined α/β-blockade is generally well tolerated, although the usual side effects associated with β-blockade (eg, fatigue) and with α-blockade (eg, dizziness) can occur. Use in asthmatics deserves caution. Interestingly, the unusual side effect of scalp tingling that is associated with labetalol does not occur when α-blockade and β-blockade are achieved with other agents. More research investigating combined α/β-blockade is needed. To fairly assess its role in the clinical management of hypertension, research should compare the antihypertensive effects of carvedilol, labetalol, or nebivolol (a β-blocker with vasodilating properties) with that of α/β-blockade achieved by administering 2 drugs. This has implications beyond the management of hypertension; it is well established that carvedilol improves outcome in patients with heart failure. Is it possible that a more bioavailable α/β-blocking regimen might provide better results? Studies are needed to better document the possible unique effect of α/β-blockade on BP reactivity and to assess the effect of combined α/β-blockade in specific populations, such as nonresponders to ACEI/diuretic combinations and individuals with labile or preprocedural hypertension. The effect of α/β-blockade on the morning BP surge and on hypertension linked to sleep apnea, both of which are at least partly sympathetically mediated, also merits study. Because the antihypertensive effect of combined α/β-blockade; involves mechanisms not specifically addressed by ACEIs, ARBs, and diuretics, this combination may provide a physiologically attractive treatment alternative for hypertension, particularly in nonresponders. In particular, it may be uniquely effective in lowering BP in individuals in whom BP elevations are sympathetically mediated. The antihypertensive efficacy of α/β-blockade and its neutral of metabolic effects argues for its greater consideration as add-on or alternative therapy for hypertension resistant to an ACEI/diuretic combination. Greater attention should be paid to α/β-blockade. Studies to assess efficacy in different subgroups of patients would be consistent with the goal of tailoring treatment to the pathophysiology of the hypertension, rather than treating all with the same regimen.
No takes yet. Share an insight, caveat, or question.
Samuel J. Mann (2007) conducted an editorial in Resistant Hypertension. Combined α/β-blockade vs. ACE inhibitor/diuretic combinations was evaluated. Combined α/β-blockade provides a physiologically attractive and effective treatment alternative for hypertension resistant to ACE inhibitor/diuretic combinations.
Synapse has enriched 10 related papers. Consider them for comparative context: